Patents by Inventor Celine Nicolazzi

Celine Nicolazzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL
    Publication number: 20230181755
    Abstract: The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with trifluoridine and tipiracil (TAS-102). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with trifluoridine and tipiracil (TAS-102) for use for treating cancer.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 15, 2023
    Inventor: Céline NICOLAZZI
  • ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND CETUXIMAB
    Publication number: 20230149557
    Abstract: The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with cetuximab. The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEA-CAM5-antibody in combination with cetuximab for use for treating cancer.
    Type: Application
    Filed: April 22, 2021
    Publication date: May 18, 2023
    Inventor: Céline NICOLAZZI
  • ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFOX
    Publication number: 20230151088
    Abstract: The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and oxaliplatin (FOLFOX). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with folinic acid, 5-fluoro-uracil and oxaliplatin (FOLFOX) for use for treating cancer.
    Type: Application
    Filed: April 22, 2021
    Publication date: May 18, 2023
    Inventor: Céline NICOLAZZI
  • ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFIRI
    Publication number: 20230087871
    Abstract: The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI) for use for treating cancer.
    Type: Application
    Filed: April 22, 2021
    Publication date: March 23, 2023
    Inventor: Céline NICOLAZZI
  • MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123
    Publication number: 20220213202
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Application
    Filed: December 30, 2021
    Publication date: July 7, 2022
    Inventors: Céline AMARA, Céline NICOLAZZI, Marielle CHIRON, Francis DUFFIEUX, Jochen BENINGA, Angela VIRONE-ODDOS, Laurent GAUTHIER, Ariane THIELENS, Benjamin ROSSI
  • Combinations of kinase inhibitors for the treatment of cancer
    Patent number: 9011863
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 21, 2015
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • Combinations of Kinase Inhibitors for the Treatment of Cancer
    Publication number: 20140271665
    Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.
    Type: Application
    Filed: July 8, 2011
    Publication date: September 18, 2014
    Applicants: Exelixis, Inc., Sanofi, Vanderbilt University
    Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS METHOD
    Publication number: 20140030265
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 30, 2014
    Applicant: AVENTIS PHARMA SA
    Inventors: Francis BLANCHE, Béatrice CAMERON, Sylvie SORDELLO, Céline NICOLAZZI, Marc TROMBE, Mark NESBIT
  • Modified soluble FGF receptor Fc fusions method
    Patent number: 8481487
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 9, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Béatrice Cameron, Sylvie Sordello, Céline Nicolazzi, Marc Trombe, Mark Nesbit
  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY
    Publication number: 20120195851
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: January 11, 2012
    Publication date: August 2, 2012
    Applicant: AVENTIS PHARMA SA
    Inventors: Francis BLANCHE, Beatrice CAMERON, Mark NESBIT, Sylvie SORDELLO, Celine NICOLAZZI, Marc TROMBE
  • Modified soluble FGF receptor Fc fusions with improved biological activity
    Patent number: 8119770
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: February 21, 2012
    Assignee: Aventis Pharma SA
    Inventors: Francis Blanche, Beatrice Cameron, Mark Nesbit, Sylvie Sordello, Celine Nicolazzi, Marc Trombe
  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WSITH IMPROVED BIOLOGICAL ACTIVITY
    Publication number: 20100061979
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: November 22, 2007
    Publication date: March 11, 2010
    Applicant: CENTELION
    Inventors: Francis Blanche, Beatrice Cameron, Mark Nesbit, Sylvie Sordello, Celine Nicolazzi, Marc Trombe